AbbVie Jeffrey Ryan Stewart sells 40,619 shares

Available on EDGAR 11/12/2026 - 05:01 PM EST Accepted by SEC EDGAR 11/12/2026 - 05:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AbbVie Inc. EVP and Chief Commercial Officer Jeffrey Ryan Stewart exercised options for 16,070 shares at $114.36 per share and 24,549 shares at $93.50 per share on November 9, 2026, and sold 40,619 shares that day at a weighted average of $293.60 per share; the sales ranged from $293.54 to $293.82. He gave 3,450 shares on November 12. No Rule 10b5-1 plan is reported. The filing lists 1,338 shares held by his spouse in trust; Stewart disclaims beneficial ownership of those shares.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Stewart Jeffrey Ryan

Role EVP, CHIEF COMMERCIAL OFFICER

Sold 40,619 shs ($11.93M)

Approx. gross sale proceeds $11.93M

Approx. exercise cost $4.13M

Type	Security	Shares	Price	Value
Gift	Common Stock, $0.01 par value	3,450	$0.00	$0.00
Exercise	Option (Right to Buy) F3	16,070	$0.00	$0.00
Exercise	Option (Right to Buy) F4	24,549	$0.00	$0.00
Exercise	Common Stock, $0.01 par value	16,070	$114.36	$1.84M
Exercise	Common Stock, $0.01 par value	24,549	$93.50	$2.30M
Sale	Common Stock, $0.01 par value F1	40,619	$293.60	$11.93M
Holding	Common Stock, $0.01 par value F2	--	--	--

Holdings After Transaction: Option (Right to Buy) — 24,550 options (Direct); Common Stock, $0.01 par value — 79,721 shares (Direct); Common Stock, $0.01 par value — 1,338 shares (Indirect, By spouse in trust)

Footnotes (4)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
2. F2. The reporting person disclaims beneficial ownership of all securities held by his spouse.
3. F3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021.
4. F4. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023.

Key Figures

Shares acquired through option exercise: 16,070 shares Option exercise price: $114.36 per share Shares acquired through option exercise: 24,549 shares +5 more

8 metrics

Shares acquired through option exercise 16,070 shares November 9, 2026; option exercise price $114.36 per share

Option exercise price $114.36 per share Options exercised November 9, 2026

Shares acquired through option exercise 24,549 shares November 9, 2026; option exercise price $93.50 per share

Option exercise price $93.50 per share Options exercised November 9, 2026

Shares sold 40,619 shares November 9, 2026

Weighted average sale price $293.60 per share November 9, 2026; sales ranged from $293.54 to $293.82 per share

Shares given as a gift 3,450 shares November 12, 2026

Shares held by spouse in trust 1,338 shares Reported holding; Stewart disclaims beneficial ownership

Key Terms

weighted average price, Rule 10b5-1, Rule 16b-3, Amended and Restated 2013 Incentive Stock Program

4 terms

weighted average price financial

"The reported sale price is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 regulatory

"No Rule 10b5-1 plan is reported"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Rule 16b-3 regulatory

"The option grant was exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

Amended and Restated 2013 Incentive Stock Program financial

"Options granted pursuant to the Amended and Restated 2013 Incentive Stock Program"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AbbVie (ABBV) shares did Jeffrey Ryan Stewart sell, and at what price?

On November 9, 2026, Stewart sold 40,619 shares at a weighted average of $293.60 per share. The sales were made at prices ranging from $293.54 to $293.82 per share. No Rule 10b5-1 plan is reported.

How many ABBV options did Jeffrey Ryan Stewart exercise, and at what prices?

On November 9, 2026, Stewart exercised options covering 16,070 shares at $114.36 per share and 24,549 shares at $93.50 per share. The options were granted under AbbVie’s Amended and Restated 2013 Incentive Stock Program and became exercisable in annual increments from 2019 through 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stewart Jeffrey Ryan

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF COMMERCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	11/09/2026		M		16,070	A	$114.36	99,241	D
Common Stock, $0.01 par value	11/09/2026		M		24,549	A	$93.5	123,790	D
Common Stock, $0.01 par value	11/09/2026		S		40,619	D	$293.6(1)	83,171	D
Common Stock, $0.01 par value	11/12/2026		G		3,450	D	$0	79,721	D
Common Stock, $0.01 par value								1,338	I	By spouse in trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)	$114.36	11/09/2026		M			16,070	(3)	02/15/2018	Common Stock	16,070	$0	0	D
Option (Right to Buy)	$93.5	11/09/2026		M			24,549	(4)	02/19/2030	Common Stock	24,549	$0	24,550	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

2. The reporting person disclaims beneficial ownership of all securities held by his spouse.

3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021.

4. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023.

	/s/ T.O. Odutayo, Attorney-in-Fact for Jeffrey R. Stewart	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)